Cystic Fibrosis Drug Developer Sionna Targets $150M IPO
Cystic fibrosis-focused drug developer Sionna Therapeutics Inc. on Monday launched plans for an estimated $150 million initial public offering, joining a growing number of biotechnology companies entering the IPO pipeline, represented...To view the full article, register now.
Already a subscriber? Click here to view full article